Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ConcertAI

Explore full profile

Accelerating insights and outcomes for patients through leading RWD, AI technology and scientific expertise

Boston, United StatesFounded 2017Biotech & Life Sciences
Valuation $1–2.5B Last recorded · 2022
Revenue $100–500M Latest reported FY
Headcount 500–1k Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for ConcertAI and the history behind them.

About ConcertAI

ConcertAI is a healthcare technology startup that operates in the field of artificial intelligence (AI) and data analytics. The company's primary focus is on accelerating trial data analysis and implementing innovative data and analytics techniques for various types of clinical trials, including randomized controlled trials (RCTs), pragmatic trials, external controls, and adaptive studies.

Read full description

The company serves a broad range of clients, including healthcare providers, research institutions, and other organizations involved in clinical trials and cancer research. By attending global conferences and symposiums, ConcertAI connects with leading experts in the field, staying updated with the latest trends and developments in radiology, hematology, and breast cancer research.

ConcertAI's business model revolves around its AI-powered software-as-a-service (SaaS) platform. The platform uses AI and data technologies to provide insights that can help advance cancer care and improve the efficiency of clinical trials. The company generates revenue by offering its platform and services to its clients on a subscription basis.

In summary, ConcertAI is a healthcare technology company that uses AI and data analytics to improve the efficiency of clinical trials and advance cancer care. It operates in a growing market, serving a diverse range of clients, and generates revenue through its AI-powered SaaS platform.

Source: Dealroom company data

At a glance

Founded
2017
Headquarters
Boston, United States
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

Series B and later2 investors entered at this stage

  • Sixth Street Growth
  • Sixth Street
Employees mapped 831 incl. 34 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 10 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
7 countries with
team presence
🇮🇳 India61.7%
🇺🇸 United States37.1%
🇸🇪 Sweden0.1%
🇬🇧 United Kingdom0.1%
🇨🇦 Canada0.1%
Top 5 of 7 shown
Web traffic by country
34K monthly visits
across markets
🇺🇸 United States57.9%
🇮🇳 India40.6%
🇯🇵 Japan1.2%
🇬🇧 United Kingdom0.9%
🇩🇪 Germany0.3%
Top 5 markets shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about ConcertAI on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ConcertAI on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.